Phase 1 N=31 Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)
Hypertension
Primary: Adverse Events (AEs) — 9; 16; 8; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 876 ng/mL
Phase 1 N=48 Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine
Influenza
Primary: Number of Participants With Maximum Systemic Reaction After Vaccination 1 — 16; 15; 9; 6 Participants
Phase 1 N=21 A Study of IMC-A12 in Advanced Solid Tumors
Tumors
Primary: Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events — 100; 85.7; 100; 85.7 percentage of participants
Phase 1 N=36 A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Heart Failure, Congestive
Primary: Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline — 0.4946; 0.3346; 0.5078; 0.3253 Liter — p=0.0029
Phase 1 N=178 A Study of Galcanezumab in Healthy Participants
Healthy
Primary: Part A: Number of Participants With an Injection Site Adverse Event — 3; 0 Participants
Phase 1 N=30 A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
Safety · Pharmacokinetics · Healthy Subjects
Primary: Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab. — 36.22; 82.44; 63.86 ug/mL
Phase 1 N=51 A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAEs) — 4; 3; 5; 2 Participants
Phase 1 N=41 A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
Advanced Cancer
Primary: Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD]) — 40 milligrams (mg)
Phase 1 N=24 Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Osteoporosis
Primary: Number of Participants With Adverse Events — 7; 6; 0; 1 Participants
Phase 1 N=13 A Study of LY3015014 in Healthy Participants With High Cholesterol
Healthy Volunteers · Hypercholesterolemia
Primary: Number of Participants With One or More Other Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs) — 3; 1; 0; 0 Participants
Phase 1 N=36 Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1066.11; 1117.31 ng/ml
Phase 1 N=30 Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1730; 1230; 1110 ng/mL
Phase 1 N=16 Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)
Human Immunodeficiency Virus-1 (HIV-1)
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439 — 28.6; 31.9; 35.5; 29.1 µM*h
Phase 1 N=17 AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Colorectal Cancer · Colorectal Neoplasms · Colorectal Carcinoma
Primary: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) — 6; 9 Participants